...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Q4 2019 Events
12
Oct 01, 2019 03:56PM
4
Oct 01, 2019 04:37PM
3
Oct 01, 2019 05:52PM
2
Oct 02, 2019 07:09AM
6
Oct 07, 2019 04:14PM
3
Oct 07, 2019 04:18PM
7
Oct 07, 2019 04:22PM
6
Oct 07, 2019 04:44PM
1
Oct 07, 2019 08:10PM
3
Oct 07, 2019 08:56PM
1
Oct 07, 2019 09:06PM

"What is your expectation about Apabetalone being accepted for ASN late breaking presentation?  Although AHA accepted us, that was for a Phase 3 trial.  ASN on the other hand is looking at a sub study of a trial.  Does that change the perception of ASN's willingness to accept our presentation?"

Good questions. I'll let you know on Friday when they announce the late breakers. Lol.

"If ASN does not accept RVX, can the same data be dumped on the AHA?  I note that we only have 8 minutes to make our case at the AHA."

At this point we don't even know if Resverlogix submitted anything for ASN. In my opinion, AHA and other cardio conferences are not good venues to present the CKD sub-study data. If not at ASN, they might just announce results and present detailed data sometime later like at June 2020 ERA-EDTA or ADA. We'll surely know more in the next two weeks after ASN late breakers are announced and after Resverlogix presents at BIO Investor. 

BearDownAZ

2
Oct 08, 2019 12:02AM
7
Oct 12, 2019 07:13AM
2
Oct 25, 2019 12:59AM
4
Oct 25, 2019 08:16AM
1
Oct 25, 2019 09:16AM
8
Nov 01, 2019 11:35AM
Share
New Message
Please login to post a reply